Liver transplantations for patients who are co-infected with HIV and HCV have always posed a challenge and still do, according to the results of a new study. This article discusses the factors that contribute to an increased risk of poor transplantation outcomes and how new treatment options might affect patient survival.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Samuel, D. et al. Are HIV infected patients candidates for liver transplantation? J. Hepatol. 48, 697–707 (2008).
Sawinsky, D. et al. Beyond the NIH multicenter HIV transplant trial experience: outcomes of HIV+ liver transplant recipients compared to HCV+ or HIV+/HCV+ coinfected recipients in the United States. Clin. Inf. Dis. http://dx.doi.org/10.1093/cid/civ471.
Duclos-Vallee, J. C. et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 47, 407–417 (2008).
Miro, J. M. et al. Outcome of HCV/HIV coinfected liver transplant recipients: a prospective and multicenter cohort study. Am. J. Transplant. 12, 1866–1876 (2012).
Antonini, T. M. et al. Fibrosing cholestatic hepatitis in HIV/HCV co-infected transplant patients—usefulness of early markers after liver transplantation. Am. J. Transplant. 11, 1686–1695 (2011).
Tateo, M. et al. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. AIDS 23, 1069–1076 (2009).
Coilly, A. et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience. J. Hepatol. 60, 78–86 (2014).
Castells, L. et al. Pegylated Interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study. J. Hepatol. 62, 92–100 (2015).
Charlton, M. et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced disease. Gastroenterology http://dx.doi.org/10.1053/j.gastro.2015.05.010.
Antonini, T. et al. P0804: Efficacy of sofosbuvir-based treatment regimens in HIV/HCV co-infected patients after liver transplantation: The ANRS CO23 CUPILT study. J. Hepatol. 62 (Suppl. 2), S635–S636 (2015).
Acknowledgements
We thank the ANRS Agence Nationale de Recherche sur Le Sida et les Hépatites for its continuous support through the programmes Thevic and Prethevic.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.S. has received consultant fees from Abbvie, Astellas Pharma, BMS, Gilead Sciences, MSD and Novartis. J.-C.D.-V. declares no competing interests.
Rights and permissions
About this article
Cite this article
Samuel, D., Duclos-Vallée, JC. The effect of new HCV drugs on liver transplantation outcomes. Nat Rev Gastroenterol Hepatol 12, 559–560 (2015). https://doi.org/10.1038/nrgastro.2015.165
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2015.165
